Your Health, We Care
Release date: 2024-08-16 16:45:53 Recommended: 277
As a highly selective RET inhibitor, Selpercatinib is used for the treatment of RET fusion-positive and mutation-associated cancers. It was approved by the FDA in 2020 and has shown good efficacy in clinical applications, especially for the treatment of non-small cell lung cancer and thyroid cancer.
Patients are advised to take Selpercatinib with meals at about the same time every day. The tablet should be swallowed whole, avoiding crushing, chewing, splitting, or dissolving the tablet.
If the patient misses a dose for more than 4 hours, or if the patient vomits after taking the medication, it is recommended to skip the dose and continue to take the medication normally at the next scheduled time without the need for a catch-up dose.
For medications in special populations, please refer to the instructions below for specific medication recommendations.
When using this medicine, pregnant women may face potential risks to the fetus. It is recommended to avoid breastfeeding during treatment and for a week after the last dose to protect the baby from possible effects of the drug. The doctor will assess the risks on a case-by-case basis and provide appropriate recommendations and alternatives.
The safety and efficacy of this drug in children under 12 years of age have not been fully validated. This group of patients should be used with particular caution, and physicians should carefully assess the risks and benefits on an individual basis and consider whether there are other more appropriate treatment options.
Drug interactions may affect the efficacy of treatment, and information on the interaction of Selpercatinib is presented below.
Concomitant use of Selpercatinib and acid-suppressing drugs (eg, PPIs, H2 receptor antagonists, topical antacids) may reduce plasma concentrations of Selpercatinib and affect the drug's efficacy.
If co-use with these drugs cannot be avoided, it is recommended to take PPIs with food, or to adjust the timing of Selpercatinib, avoiding H2 receptor antagonists and topical antacids.
The use of Selpercatinib as a P-gp inhibitor in combination with P-gp substrates may increase the plasma concentration of these substrates and increase the risk of related adverse effects. If it must be used at the same time, refer to the instructions of the substrate drug to make the necessary adjustments.
[Warm tips] Taking the drug at the same time every day can help to maintain a stable blood concentration of the drug and improve the therapeutic effect. If you're prone to forgetting, you can set reminders to help you get your medication on time.
